APA (7th ed.) Citation

Cai, L., Li, C., Li, S., Zhang, X., Wang, G., Yu, J., . . . Zhang, J. (2025). Correction: Investigation of the Efficacy and Safety of Xeligekimab (GR1501) in Patients with Moderate-to-Severe Plaque Psoriasis: A Multicenter, Randomized, Double-Blind Phase II Clinical trial. Dermatology & Therapy, 15(10), 2817. https://doi.org/10.1007/s13555-025-01480-5

Chicago Style (17th ed.) Citation

Cai, Lin, et al. "Correction: Investigation of the Efficacy and Safety of Xeligekimab (GR1501) in Patients with Moderate-to-Severe Plaque Psoriasis: A Multicenter, Randomized, Double-Blind Phase II Clinical Trial." Dermatology & Therapy 15, no. 10 (2025): 2817. https://doi.org/10.1007/s13555-025-01480-5.

MLA (9th ed.) Citation

Cai, Lin, et al. "Correction: Investigation of the Efficacy and Safety of Xeligekimab (GR1501) in Patients with Moderate-to-Severe Plaque Psoriasis: A Multicenter, Randomized, Double-Blind Phase II Clinical Trial." Dermatology & Therapy, vol. 15, no. 10, 2025, p. 2817, https://doi.org/10.1007/s13555-025-01480-5.